Adoptive T-cell immunotherapy of cancer

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 2, 1999, Pages 105-117

  Li, Qiao ^a   Chang, Alfred E ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b 3302 Cancer Center ^*  (United States)

Author keywords

Adoptive immunotherapy; CD28; CD3; IL 2; Neoplasm; T cell; Tumor infiltrating lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; EFFECTOR CELL; GENE TRANSFER; HUMAN; KIDNEY CANCER; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, NEOPLASM; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 0032802355     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Billingham R, Brent L, Medawar P, Quantitative studies on tissue transplantation immunity: the origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Biol (1954) 143: 58-80.
2. Mitchison N, Studies on the immunological response to foreign tumor transplants in the mouse: the role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med (1955) 102: 157-77.
3. Borberg H, Oettgen HF, Choudry K, Beattie EJ Jr, Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors. Int J Cancer (1972) 10: 539-47.
4. Morgan D, Ruscetti F, Gallo R, Selective in vitro growth of T lymphocytes from normal human bone marrow. Science (1976) 193: 1007-8.
5. Grimm EA, Robb RJ, Roth JA et al, Lymphokine-activated killer cell pehnomenon, III: evidence that IL-2 is sufficient for direct activation of peripheral blood into lymphokine-activated killer cells. J Exp Med (1983) 158: 1356-61.
6. Mulé J, Shu S, Schwarz SL, Rosenberg SA, Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 225: 1487-9.
7. Lafreniere R, Rosenberg SA, Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735-41.
8. Rosenberg SA, Lotze MT, Muul LM et al, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 313: 1485-92.
9. McCabe M, Stablein D, Mawkins M, The modified group C experience - phase III randomized trials of IL-2 vs. IL-2/LAK in advanced renal cell cancer and advanced melanoma. Proc Am Soc Clin Oncol (1991) 10: 213 (Abst 714).
10. Rosenberg SA, Lotze MT, Topalian SL et al, Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 85: 622-32.
11. Curti BD, Longo DL, Ochoa AC et al, Treatment of cancer patients with ex vivo anti-CD3 activated killer cells and interluekin-2. J Clin Oncol (1994) 11: 652-60.
12. Ting C-C, Hargrove M, Yun Y, Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. J Immunol (1988) 141: 741-8.
13. Anderson P, Blazar B, Bach F, Ochoa A, Anti-CD3 + IL-2 stimulated murine killer cells in vitro generation and in vivo antitumor activity. J Immunol (1989) 142: 1383-94.
14. Rosenberg S, Speiss P, Lafreniere P, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 233: 1318-21.
15. + tumor-infiltrating lymphocytes. J Exp Med (1991) 173: 647-58.
16. Schwartzentruber S, Topalian S, Mancini M, Rosenberg SA, Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infil-trating lymphocytes after autologous tumor stimulation. J Immunol (1991) 146: 3674-81.
17. Schwartzentruber DJ, Hom SS, Dadmarz R et al, In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol (1994) 12: 1475-83.
18. Spiess P, Yang JC, Rosenberg SA, In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst (1987) 79: 1067-75.
19. Topalian SL, Solomon D, Rosenberg SA, Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 142: 3714-25.
20. Rosenberg SA, Yannelli JR, Yang JC et al, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst (1994) 86: 1159-65.
21. Ridolfi R, Flamini E, Riccobon A et al. Adjuvant adoptive immunotherapy with tumor-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Cancer Immunol Immunother (1998) 46: 185-93.
22. Shu S, Chou T, Rosenberg SA, Generation from tumor-bearing mice of lymphoid cells with in vivo therapeutic efficacy. J Immunol (1987) 139: 295-304.
23. Chou T, Chang AE, Shu S, Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J Immunol (1988) 140: 2453-61.
24. Chou T, Bertera S, Chang AE, Shu S, Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol (1988) 141: 1775-81.
25. Chang AE, Shu S, Current status of adoptive immunotherapy of cancer. Clin Rev Oncoll Hematol (1996) 22: 213-28.
26. Shu S, Chou T, Sakai K, Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol (1989) 143: 740-8.
27. Geiger J, Wagner P, Shu S, Chang AE, A novel role for autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol (1992) 1: 199-208.
28. Geiger J, Wagner P, Cameron M et al, Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother (1993) 13: 153-65.
29. Chang AE, Yoshizawa H, Sakai K et al, Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res (1993) 53: 1043-50.
30. Chang AE, Aruga A, Cameron MJ et al, Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol (1997) 15: 796-807.
31. Area M, Krauss JC, Aruga A et al, Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther (1996) 3: 39-47.
32. + T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med (1992) 175: 1423-31.
33. Fearon ER, Pardoll DM, Itaya T et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60: 397-403.
34. Asher AL, Mulé JJ, Kasid A et al, Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol (1991) 146: 3227-34.
35. Gansbacher B, Gastl G, Finstad CL et al, Retroviral vectormediated α-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res (1990) 50: 7820-5.
36. Golumbek PT, Lazenby AJ, Levitsky HI et al, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 254: 713-16.
37. Colombo MP, Ferrari G, Stoppacciaro A et al, Granulocyte colony-stimualting factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 173: 889-97.
38. Mullen CA, Coale MM, Levy A et al, Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res (1992) 52: 6020-4.
39. Connor J, Bannerji R, Saito S et al, Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med (1993) 177: 1127-34.
40. DRanoff G, Jaffe E, Lazenby A et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and longlasting antitumor immunity. Proc Natl Acad Sci USA (1993) 90: 3539-43.
41. Plautz G, Zhi-Yong Y, Bei-Yue W et al, Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA (1993) 90: 4645-9.
42. Wahl WL, Plautz GE, Fox B et al, Generation of therapeutic T lymphocytes after in vivo transfection of a tumor with a gene encoding allogeneic class I major histocompatability complex antigen. Surg Forum (1992) 63: 476-8.
43. Nabel GJ, Gorson D, Bishop DK et al, Immune response in human melanoma after transfer of an allogeneic class I major histocompatability complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA (1996) 93: 15388-93.
44. Cerottini JC, Liénard D, Romero P, A new era for human cancer immunology. Immunologist (1997) 5: 27-31.
45. Houghton A, Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 180: 1-4.
46. Parmiani G, Tumor immunity as auto immunity: tumor antigens include normal self-proteins which stimulate anergic peripheral T cells. Immunol Today (1993) 14: 536-8.
47. van der Bruggen P, Traversari C, Chomez P et al, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254: 1643-8.
48. Van Pel A, van der Gruggen P, Couli PG et al, Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Res (1995) 145: 229-50.
49. Wang RF, Parkhurst MR, Kawakami Y et al, Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med (1996) 183: 1131-40.
50. Greenberg P, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 49: 281-355.
51. Yoshizawa H, CHang AE, Shu S, Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol (1991) 147: 729-37.
52. Goedegebuure PS, Zuber M, Leonard-Vidal DL et al, Reactivation of murine tumor-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol (1994) 3: 79-89.
53. Cheever MA, Greenberg PD, Fefer A, Gillis S, Augmentation of antitumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J Exp Med (1982) 155: 968-80.
54. Eberlein T, Rosenstein M, Rosenberg SA, Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin-2. J Exp Med (1982) 156: 385-97.
55. Stephenson K, Perry-Lalley D, Griffith K et al, Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts. Surgery (1989) 105: 523-8.
56. Yoshizawa H, Sakai K, Chang AE, Shu S, Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol (1991) 134: 473-9.
57. Aruga A, Aruga E, Tanigawa K et al, Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determined in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol (1997) 159: 664-73.
58. June C, Ledbetter J, Linsley P, Thompson C, Role of the CD28 receptor in T cell activation. Immunol Today (1990) 11: 211-16.
59. Dubey C, Croft M, Swain S, Naive and effector CD4 T cells difrer in their requirements for T cell receptor versus costimulatory signals. J Immunol (1996) 157: 3280-9.
60. + T cells. J Exp Med (1994) 179: 1539-49.
61. + T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res (1999) 5: 461-9.
62. Tuttle TM, Inge TH, Bethke KP et al, Activation and growth of murine tumor-specific T cells which have in vivo activity with Bryostatin 1. Cancer Res (1992) 52: 548-553.
63. Tuttle TM, Inge TH, Wirt CP et al, Bryostatin 1 activates T cells that have antitumor activity. J Immunother (1992) 12: 75-81.
64. Tuttle TM, Inge TH, Lind DS, Bear HD, Adoptive transfer of Bryostatin 1-activated T cells provides long-term protection from tumour metastases. Surg Oncol (1992) 1: 299-307.
65. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes, J Immunol (1998) 160: 3444-52.
66. Shu S, Sussman J, CHang AE. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T cell reagents. J Immunother (1993) 14: 279-85.
67. Shu S, Krinock RA, Matsumura T et al, Stimulation of tumor-draining lymph node cells with superantigenic staphyloccocal toxins leads to the generation of tumor-specific effector cells. J Immunol (1994) 152: 1277-88.
68. Finn OJ, Person DA, Pirami L et al, Retroviral trasnduction of protein kinase C-gamma into cytotoxic T lymphocyte clones leads to immortalization with retention of specific function. J Immunol (1991) 146: 1099-103.
69. Chen W, Schweins E, Finn OJ et al, Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo. J Immunol (1994) 153: 3630-8.
70. Nakamura Y, Wakimoto H, Kanegae Y et al, Adoptive immunotherapy with murine tumor specific T lymphocytes engineered to secrete interleukin-2. Cancer Res (1994) 54: 5757-60.
71. Eshhar Z, Waks T, Schindler DG, Gross G, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody binding domains and the γ or ζ subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA (1993) 90: 720-4.
72. Stancovski I, Schindler D, Waks T, Targeting of T lymphocytes to Neu/Her2 expressing cells using chimeric single chain Fv receptors. J Immunol (1993) 151: 6577-82.
73. Moritz D, Wels W, Groner B, Mattern J, Cytotoxic T lymphocytes with a grafted recognition specificity of DRBB2-expressing tumor cells. Proc Natl Acad Sci USA (1994) 91: 4318-22.
74. Hwu P, Shafer G, Treisman J, Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med (1993) 178: 361-6.
75. Hwu P, Yang T, Cowherd R et al, In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes. Cancer Res (1995) 55: 3369-73.
76. Rosenberg SA, Aebersold P, Cornetta K et al, Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 323: 570-8.
77. Economou J, Belldegrun AS, Glaspy J et al, In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double blind gene marking trial. J Clin Invest (1996) 97: 515-21.
78. Traversari C, Van der Bruggen P et al, A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med (1992) 176: 1453-7.
79. + T cells specifically recognize a shared melanoma associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA (1996) 91: 9461-5.
80. Jerome K, Barnd D, Bendt K et al, Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res (1991) 51: 2908-16.
81. Gaudin C, Krerner F, Angevin E et al, A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol (1999) 162: 1730-8.
82. Cole D, Weil DP, Shilyanski J et al, Characterization of the functional specificity of a cloned T cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res (1995) 55: 748-52.